A SUPER-powered WP Engine Atlas Test Site

Joe&#039;s Atlas Experimentation Site

Scientists have created new &#8220;molecular traps&#8221; that were able to improve survival in cell and fruit fly models of <a href="https://alsnewstoday.com/what-is-als/">amyotrophic lateral sclerosis</a> (ALS) associated with mutations in the gene C9ORF72.
The traps bind to the toxic small proteins that arise from the mutated C9ORF72 gene and have a harmful effect on protein production and cell survival. The traps may offer a new approach to protect neurons from such damaging proteins, said researchers in &#8220;<a href="https://www.science.org/doi/10.1126/sciadv.adf7997">CLIP-Seq analysis enables the design of protective ribosomal RNA bait oligonucleotides against C9ORF72 ALS/FTD poly-GR pathophysiology</a>,&#8221; which was published in <a href="https://www.science.org/journal/sciadv">Science Advances</a>.
Mutations in the gene C9ORF72 are the most common known <a href="https://alsnewstoday.com/causes-of-als/#Genetics_of_ALS">genetic cause of ALS</a>. Disease-causing mutations in this gene lead to abnormal proteins called dipeptide repeat proteins, or DPRs, being produced, which are toxic to nerve cells.
DPRs can stick to other proteins in cells and it&#8217;s long been thought this is mainly what makes them toxic. But they also can stick to ribonucleic acid (RNA), scientists discovered here.
RNA is an intermediary molecule made when genes are &#8220;read&#8221; to create proteins. The genetic code is copied from a cell&#8217;s DNA into RNA, which is used as a template to make protein by ribosomes, the cell&#8217;s protein-making machines. Ribosomes also contain specialized RNA molecules that help them &#8220;read&#8221; RNA to create proteins.
[recommended-reading id=37937]
<h3>Making a better &#8216;molecular trap&#8217;</h3>
Through molecular testing, the researchers demonstrated that a specific DPR known as poly-glycine-arginine (poly-GR) can bind to the RNA inside ribosomes. The scientists figured out where the poly-GR protein and the ribosomal RNA molecules were interacting and showed that these interactions could interfere with ribosomes&#8217; job of making new proteins.
&#8220;We found that poly-GR directly binds to multiple [ribosomal] RNA species in cells and impedes ribosomal [normal functioning],&#8221; the scientists wrote.
This &#8220;interaction between Poly-GR and the [ribosomal] RNA is stronger than the interaction between the Poly-GR with other ribosomal proteins that had been previously described in other studies, and it tells us why these dipeptides have a high affinity for binding to ribosomes in cells,&#8221; Juan Alberto Ortega Cano, PhD, a co-author of the study at the University of Barcelona in Spain, said in a <a href="https://web.ub.edu/en/web/actualitat/w/new-therapeutic-strategy-to-reduce-neuronal-death-in-amyotrophic-lateral-sclerosis?tn=np">press release</a>.
Based on these findings, the scientists created &#8220;molecular traps,&#8221; the basic idea being to make an RNA molecule with a similar structure to the ribosomal RNA that could act as &#8220;bait&#8221; to draw away the toxic poly-GR.
In a lab model of human nerve cells carrying ALS-causing C9ORF72 mutations, treatment with the molecular traps led to significant improvements in cellular survival.
&#8220;It reduces the defects in ribosome biosynthesis in protein translation and toxicity in cells expressing Poly-GR, as well as death in motor neurons of ALS patients with mutations in the C9orf72 gene,&#8221; Cano said.
The molecular traps also improved survival outcomes in a fruit fly model of ALS caused by this mutation.
&#8220;Although more work is required to understand how the binding of [these molecular traps] to poly-GR alleviates its pathophysiology, the promising results we present here support the notion that using bait RNAs is useful not only to study RNA-protein interactions, but also to protect neurons from the detrimental effects of mutant or aberrant proteins,&#8221; the scientists said.

‘Molecular traps’ may help fend off nerve damage from gene mutations

An immune protein that is mostly produced in neurons was found to drive damage to mitochondria, which produce energy for cells, and nerve fiber loss, a study has found.
Suppressing the protein, called gasdermin-E (GSDME), prevented nerve fiber loss in cells derived from people with <a href="https://alsnewstoday.com/what-is-als/">amyotrophic lateral sclerosis</a> (ALS), and also prolonged survival and improved motor function in an ALS mouse model.
Researchers noted that understanding the details of GSDME-mediated nerve damage may support the development of new <a href="https://alsnewstoday.com/als-treatment/">therapeutic strategies</a> for neurodegenerative diseases.
“The unmet need for therapies for neurodegenerative diseases is huge, and our work opens up a whole new pathology that we could address,” Judy Lieberman, MD, PhD, professor at Harvard Medical School (HMS) and study co-lead said in a <a href="https://hms.harvard.edu/news/new-insights-als">university press release</a>.
“We describe a pathway and molecules that you can target for treating many neurodegenerative diseases,” said Lieberman, who is also chair of cellular and molecular medicine at Boston Children’s Hospital.
[recommended-reading id=21684]
The discovery was described in the study “<a href="https://www.cell.com/neuron/fulltext/S0896-6273(23)00123-X?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS089662732300123X%3Fshowall%3Dtrue">Gasdermin-E mediates mitochondrial damage in axons and neurodegeneration</a>,” which was published in the journal <a href="https://www.cell.com/neuron/home">Neuron</a>.
ALS is marked by the shrinkage and death of motor neurons, the nerve cells that send messages between the nervous system and muscles to control voluntary movements. In neurological diseases such as ALS, nerve cell death is often preceded by the impaired function of mitochondria and the loss of nerve fibers called axons.
<h3>Gasdermins are proteins linked to cell death</h3>
Gasdermins (GSDMs) are a family of proteins linked to cell death via a process called pyroptosis — a form of death triggered by the formation of pores in the cell membrane. Pyroptosis occurs <a href="https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-01959-x">most often upon infection</a> and is thought to be part of the antimicrobial response, but it has also been associated with disease-related inflammation.
“Inflammation is a double-edged sword and could be either protective or destructive based on context,” said Isaac Chiu, PhD, associate professor of immunology at HMS and study co-lead.
GSDME is a GSDM family member produced in the brain and spinal cord, but its role in nerve cell function remains largely unknown. The team at Harvard set out to address that question.
The protein was found to be activated when neurons were exposed to chemicals that are toxic to mitochondria to model features of neurodegeneration. GSDME specifically targeted the membranes within mitochondria, where it caused pores that released the mitochondrial content to mediate neuronal damage.
Consistently, mouse neurons modified to lack GSDME showed greater mitochondrial integrity and resistance to the toxic chemicals. Overall, evidence indicated that GSDME regulated the integrity of axons, and when activated locally, it destroyed mitochondria and damaged axons without affecting neuron cell bodies.
“If you look at a plate of neurons, you see a jungle of axons,” said Himanish Basu, PhD, co-first author of the study. “But if you look at a plate where gasdermin E is activated, you see retractions of these cellular processes.”
[recommended-reading id=82904]
<h3>GSDME contributed to mitochondrial dysfunction, axon loss</h3>
To understand whether GSDME could contribute to the neuronal death caused by ALS-associated proteins, the team grew mouse and human-derived neurons with TDP43 and PR-50 — a product of C9ORF72 mutations. This exposure induced GSDME activation and caused mitochondrial dysfunction and axon loss.
In contrast, exposure to these proteins did not impact axons in cells lacking GSDME. The team noted these results mirrored those obtained using mitochondrial toxins.
“Our work is an example of how immunology can help explain neurodegeneration on a mechanistic level, and what drives axon loss and neuronal injury,” said Dylan Neel, a graduate student in Chiu’s lab and a co-first author.
Finally, the team tested the impact of GSDME in a standard ALS mouse model, which developed progressive loss of motor neurons in the spinal cord. The researchers detected activated GSDME in the spinal cords of symptomatic ALS mice, increasing further by the late stages of the disease, but the protein was not found in pre-symptomatic animals.
Deleting GSDME in ALS mice improved motor function, prevented axon and motor neuron loss, and reduced nerve-related inflammation, which ultimately extended the animals&#8217; survival.
“We identify GSDME as an executioner of neuronal mitochondrial dysfunction that may contribute to neurodegeneration,” the researchers wrote. “Future work should determine the feasibility of targeting GSDME expression or function.”
Chiu added: “We revealed an innate immune molecule playing a role in neurodegeneration, which presents a new avenue of thinking about neuronal health.”

Tag: nerve damage

‘Molecular traps’ may help fend off nerve damage from gene mutations

This immune protein plays key role in nerve damage, early study finds